prices nor sold bulk drug to others at notional price;

(c) what was the price of bulk drug on which formulation prices were based when the company applied for stay order and upto when the same prices were maintained;

(d) whether it is also a fact that stay was granted based on certain conditions;

(e) if so. what are the details thereof;

(f) whether it is a fact that his Ministry directed Special Team to calculate liability on notional price; and

(g) if so, when and on what basis such direction was issued ?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) Notional price was communicated by the company in the data submitted to the Government in the year 1977.

(b) In their formulations M/s Hoechst took a price of Rs. 24735.38 per kg. in respect of Baralgone Ketone under DPCO, 1970.

(c) The formulation price at the time of stay was based on Baralgon Ketone price of Rs. 24735.38 per kg.

(d) and (e) The stay was granted to the company after taking undertaking from them for depositing the difference in the price of the formulations in question if the petition is dismissed.

(f) and (g) Special Team was required to assess the amounts due based on the Supreme Court judgement and the provisions of Drugs (Prices Control) Order, 1979.

Increase in the prices of medicines

2881. SHRI H. HANUMANTHAPPA:
SHRI DHULESHWAR MEENA:

Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unstarred Question 900 given in the Rajya Sabha on the 13th August, 1990 and state:

(a) What was the price of leader and follower brand of finished medicines based on each drug before DPCO 1987 and on 20th August, 1990 for which his Ministry received representations from Members of Parliament against wrong exclusion of drugs and what is the percentage increase or decrease in each case;

(b) whether tt is a fact that it is obligatory for producers to submit break up for non-scheduled formulations:

(c) tf so, what are the names of finished medicines where producers have taken more than 150 percent MAPE;

(d) what is the exclusion criterta based on which each drug was excluded and whether his Ministry verified the exclusion criteria; and

(e) whether it is also a fact that his Ministry found discrepencies-, if so. what are the details there of ?

THE MINISTER OF PETROLEUM AND CHEMICALS (SHRI M. S. GURUPADASWAMY): (a) There are about 165 bulk drugs on which representations against wrong exclusion from price control have been received from Hon'ble Members of Parliament. The formulations based on these bulk drugs wtll run into several hundreds. The time and labour involved in tabulating the required data will not be commensurate with the results likely to be achieved.

(b) Yes; Sir.

(c) A Statement giving the names of certain popular brands where MAPE of more 150% has been charged is annexed. (*See* below).

(d) and (e) The inclusion/exclusion of bulk drugs under price control under the Drugs (Prices Control) Order, 1987 is based on the recommendations made by the Kelkar Committee in its main as well as Supplementary Report, copies of which are available in the Parliament. On receiving a number of representations that certain drugs did not fulfil any of the exclusion criteria but are still out of price control, the Standing Committee, constituted by this Department, is looking into all such cases.

Statement

S. No.	Name of Formulations
1	Waterburry's Comp. 250 ml
2.	Do. 470 ml
3.	Listerine 200 ml. Bottle
4.	Do. 400 ml. Bottle
5.	Citralka Liquid 114 ml. Bottle
6.	Peritrate Tabs. 10's
7.	Peritrate SA Tabs. 10's
8.	Takazyne 75 gm.
9.	Demolox Tabs. 50 mg.
10.	Demolox Tabs 100 mg.
11.	Felvit Folic Acid Tabs.
12.	Chlortetracycline Soluble Powder 100 gm.
13.	Chloytetracycline Soluble Powder 500 gm.
14.	Decadurabolin Inj. 10 mg.
15.	Decadurabolin Inj. 25 mg.
16.	Docabolin Inj.
17.	Lynoral Tabs. 0.01 mg.
18.	Lynoral Tabs. 0.05 mg.
19.	Durabolin Inj. 25 mg.
20.	Mixogen Tabs.
21.	Mixogen Inj.
22.	Sustanon Inj. 100
23.	Sustanon Inj. 250
24.	Depicor Caps. 10's (5 mg.)
25.	Depicor Caps (10 mg.) 10's
26.	Selsun suspension 2.5% 120 ml.
27.	Pentothal Sodium 0.5 gm. vial
28.	Erythromycin Oint. 10 gm. tube
29.	Rumenton Tabs 50's tin
30.	Karvol Inhalant Caps. 12 bottles

Expenditure on advertisements by drug companies.

2882. SHRI SIKANDER BAKHT :
SHRI ANANT RAM JAISWAL:

Will the Minister of PETROLEUM AND CHEMICALS be pleased to refer to the answer to Unstarred Question 833 given in the Rajya Sabha on the 16th August, 1990 and state:

(a) whether his Ministry have made any study of the expenditure incurred by drug companies on advertisements and promotional activities.;

(b) if so, what are the details thereof;

(c) whether it is a fact that his Ministry are reviewing the drug policy and reconsidering the mark up aspect;

(d) if so, what are the considerations and data on which his Ministry would base the decision about reasonable mark up in the absence of advertisement expenditure study;